1953 Program Over The Next 6 Months
11/02/2026 12:04
Feb 11 (Reuters) - Vyome Holdings Inc HIND.O: VYOME FILES FOR VT-1953 ORPHAN DRUG STATUS, FURTHERS STRATEGIC FOCUS ON VT-1953 PROGRAM OVER THE NEXT 6 MONTHS VYOME HOLDINGS INC - ORPHAN DRUG STATUS CONFERS $3M PDUFA FEE WAIVER VYOME HOLDINGS INC - FDA INTERACTIONS PLANNED IN Q2 2026 FOR PHASE 3 PROTOCOL Source text: ID:nBw7BD0WBa Further company coverage: HIND.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vyome Holdings
See all newsBrief: Vyome - Appoints Jerry Leonard As CFO On August 27, 2026 - SEC Filing
Biopharma firm Vyome Holdings posts Q2 net loss
Vyome Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Vyome Holdings Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity